𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Synthesis of [3H]ABT-518, a matrix metalloproteinase inhibitor (MMPI) labeled in the phenyl rings

✍ Scribed by Shirish N. Raja; Bruce W. Surber; Jia Du; Jeffrey L. Cross

Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
131 KB
Volume
52
Category
Article
ISSN
0022-2135

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

A novel matrix metalloproteinase inhibitor, ABT‐518, [S‐(R^*^, R^*^)]‐N‐[1‐(2, 2‐dimethyl‐1,3‐dioxol‐4‐yl)‐2‐[[4‐[4‐(trifluoromethoxy)‐phenoxy]phenyl]sulfonyl]ethyl]‐N‐hydroxyformamide, was labeled with tritium in two phenyl rings in a seven‐step synthesis. The overall radiochemical yield of [^3^H]ABT‐518 in seven steps starting from 1‐(methylsulfonyl)‐4‐[4‐(trifluoromethoxy)phenoxy]benzene was 6.2% with the radiochemical purity of 99.4%. Copyright © 2009 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Synthesis of [14C]ABT-770, matrix metall
Synthesis of [14C]ABT-770, matrix metalloproteinase inhibitor (MMPI), labelled in the phenoxy ring
✍ Shirish N. Raja 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 120 KB

## Abstract The MMPI [^14^C]ABT‐770 **(1)**, __N‐__[__(1S)__‐1‐[(4,4‐Dimethyl‐2,5‐dioxo‐1‐imi‐dazolidinyl)methyl]]‐2‐[[4′‐(trifluoromethoxy)[1,1′‐biphenyl]‐4‐yl]oxy]ethyl]‐__N__‐hydroxyformamide was synthesized in 8 steps using 4‐bromophenol‐UL‐^14^C **(10)** as a starting material. The Carbon‐14 l

Quantitative analysis of the novel antic
Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry
✍ E. Stokvis; H. Rosing; M. Crul; M. J. Rieser; A. J. R. Heck; J. H. M. Schellens; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 245 KB 👁 2 views

## Abstract A liquid chromatographic/tandem mass spectrometric (LC/MS/MS) assay for the quantitative analysis of the novel anticancer drug ABT‐518 and the screening of six potential metabolites in human plasma has been developed and validated to support a phase I study with the drug. ABT‐518 is an